Syndax Pharmaceuticals Inc - Common Stock (SNDX)

Historical Holders from Q1 2016 to Q1 2025

Symbol
SNDX on Nasdaq
CUSIP
87164F105
Type / Class
Equity / Common Stock
Shares outstanding
86.5M
All holders as of December 31, 2024
Q4 2024
Shares, excl. options
98M
Holdings value
$1.3B
% of all portfolios
0.008%
Grand Portfolio weight change
+0%
Number of holders
217
Number of buys
113
Number of sells
-88
Average Value change %
+0%
Average buys %
+0.003%
Average sells %
-0.003%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Syndax Pharmaceuticals Inc - Common Stock (SNDX)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Kynam Capital Management, LP 9.98% $107M 8.52M Kynam Capital Management, LP Dec 31, 2024
BlackRock, Inc. 7.8% $84.5M 6.74M BlackRock, Inc. Mar 31, 2025
GOLDMAN SACHS GROUP INC 7% $74.6M 5.95M THE GOLDMAN SACHS GROUP, INC. Dec 31, 2024
MORGAN STANLEY 6.3% $67.2M 5.36M Morgan Stanley Dec 31, 2024
Point72 Asset Management, L.P. 5% $53.6M 4.28M Point72 Asset Management, L.P. Jan 21, 2025
WELLINGTON MANAGEMENT GROUP LLP 0% $447K 35.7K Wellington Management Group LLP Feb 28, 2025

Institutional Holders of Syndax Pharmaceuticals Inc - Common Stock (SNDX)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q1 2.18M $26.8M -$50.8K $12.29 11
2024 Q4 98M $1.3B +$87.3M $13.22 217
2024 Q3 89M $1.71B +$22.8M $19.25 210
2024 Q2 87.3M $1.79B -$71.1M $20.53 194
2024 Q1 90.3M $2.15B +$42.5M $23.80 189
2023 Q4 88.7M $1.92B +$382M $21.61 175
2023 Q3 71M $1.03B -$1.57M $14.52 173
2023 Q2 70.5M $1.47B -$31.6M $20.93 163
2023 Q1 73M $1.54B +$25.3M $21.12 160
2022 Q4 71.3M $1.82B +$263M $25.45 154
2022 Q3 59.5M $1.43B +$97.8M $24.03 130
2022 Q2 54.5M $1.05B +$14.5M $19.24 111
2022 Q1 54.4M $945M +$26M $17.38 133
2021 Q4 52.3M $1.14B +$54.3M $21.89 128
2021 Q3 48.9M $935M -$21.2M $19.11 121
2021 Q2 50M $859M +$11.9M $17.17 113
2021 Q1 48.5M $1.08B +$47.1M $22.36 130
2020 Q4 46.4M $1.03B +$270M $22.24 139
2020 Q3 34.2M $505M +$23.5M $14.76 97
2020 Q2 32.3M $479M +$173M $14.82 94
2020 Q1 20.7M $227M +$45.3M $10.97 78
2019 Q4 14.5M $127M -$3.74M $8.78 68
2019 Q3 15M $112M -$713K $7.47 68
2019 Q2 14.9M $139M +$4.61M $9.31 66
2019 Q1 17M $89M +$8.08M $5.25 64
2018 Q4 15.4M $68.6M -$2.85M $4.45 71
2018 Q3 15.3M $124M +$3.41M $8.08 71
2018 Q2 15.1M $106M -$23.3M $7.02 81
2018 Q1 17.2M $244M +$5.21M $14.23 72
2017 Q4 16M $140M +$23M $8.76 75
2017 Q3 15M $176M -$8.28M $11.70 67
2017 Q2 15.7M $219M +$56.8M $13.97 63
2017 Q1 11.7M $160M +$30.2M $13.72 62
2016 Q4 11.1M $79.7M -$4.87M $7.17 53
2016 Q3 11.6M $176M +$19.9M $15.16 44
2016 Q2 10.3M $101M +$10.8M $9.85 46
2016 Q1 9.44M $126M +$126M $13.32 26